The association between tumor mutational burden and prognosis is dependent on treatment context

In multiple cancer types, high tumor mutational burden (TMB) is associated with longer survival after treatment with immune checkpoint inhibitors (ICI). The association of TMB with survival outside of the immunotherapy context is poorly understood. We analyzed 10,233 patients (80% non-ICI-treated, 2...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Nat Genet
Asıl Yazarlar: Valero, Cristina, Lee, Mark, Hoen, Douglas, Wang, Jingming, Nadeem, Zaineb, Patel, Neal, Postow, Michael A., Shoushtari, Alexander N., Plitas, George, Balachandran, Vinod P., Smith, J. Joshua, Crago, Aimee M., Roche, Kara C. Long, Kelly, Daniel W., Samstein, Robert M., Rana, Satshil, Ganly, Ian, Wong, Richard J., Hakimi, A. Ari, Berger, Michael F., Zehir, Ahmet, Solit, David B., Ladanyi, Marc, Riaz, Nadeem, Chan, Timothy A., Seshan, Venkatraman E., Morris, Luc G.T.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7796993/
https://ncbi.nlm.nih.gov/pubmed/33398197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41588-020-00752-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller